These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36507500)

  • 1. Targeted alpha therapy with the
    Tornes AJK; Stenberg VY; Larsen RH; Bruland ØS; Revheim ME; Juzeniene A
    Front Med (Lausanne); 2022; 9():1058863. PubMed ID: 36507500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting with
    Juzeniene A; Stenberg VY; Bruland ØS; Revheim ME; Larsen RH
    Front Med (Lausanne); 2022; 9():1051825. PubMed ID: 36733936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of
    Westrøm S; Generalov R; Bønsdorff TB; Larsen RH
    Nucl Med Biol; 2017 Aug; 51():1-9. PubMed ID: 28486098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD46 targeted
    Li J; Huang T; Hua J; Wang Q; Su Y; Chen P; Bidlingmaier S; Li A; Xie Z; Bidkar AP; Shen S; Shi W; Seo Y; Flavell RR; Gioeli D; Dreicer R; Li H; Liu B; He J
    J Exp Clin Cancer Res; 2023 Mar; 42(1):61. PubMed ID: 36906664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the PSMA-Binding Ligand
    Stenberg VY; Larsen RH; Ma LW; Peng Q; Juzenas P; Bruland ØS; Juzeniene A
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pb-214/Bi-214-TCMC-Trastuzumab inhibited growth of ovarian cancer in preclinical mouse models.
    Metebi A; Kauffman N; Xu L; Singh SK; Nayback C; Fan J; Johnson N; Diemer J; Grimm T; Zamiara M; Zinn KR
    Front Chem; 2023; 11():1322773. PubMed ID: 38333550
    [No Abstract]   [Full Text] [Related]  

  • 7. 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Br J Cancer; 2013 May; 108(10):2013-20. PubMed ID: 23632482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model.
    Yong KJ; Milenic DE; Baidoo KE; Kim YS; Brechbiel MW
    Cancer Med; 2013 Oct; 2(5):646-53. PubMed ID: 24403230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor Activity of Novel Bone-seeking, α-emitting
    Juzeniene A; Bernoulli J; Suominen M; Halleen J; Larsen RH
    Anticancer Res; 2018 Apr; 38(4):1947-1955. PubMed ID: 29599310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.
    Meredith R; Torgue J; Shen S; Fisher DR; Banaga E; Bunch P; Morgan D; Fan J; Straughn JM
    J Nucl Med; 2014 Oct; 55(10):1636-42. PubMed ID: 25157044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).
    Ballangrud AM; Yang WH; Charlton DE; McDevitt MR; Hamacher KA; Panageas KS; Ma D; Bander NH; Scheinberg DA; Sgouros G
    Cancer Res; 2001 Mar; 61(5):2008-14. PubMed ID: 11280760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry.
    Aurlien E; Larsen RH; Akabani G; Olsen DR; Zalutsky MR; Bruland OS
    Int J Radiat Biol; 2000 Aug; 76(8):1129-41. PubMed ID: 10947126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methodology for labeling proteins and peptides with lead-212 (212Pb).
    Baidoo KE; Milenic DE; Brechbiel MW
    Nucl Med Biol; 2013 Jul; 40(5):592-9. PubMed ID: 23602604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early immunohistochemical detection of pulmonary micrometastases in dogs with osteosarcoma.
    Kerboeuf M; Koppang EO; Haaland AH; Lingaas F; Bruland ØS; Teige J; Moe L
    Acta Vet Scand; 2021 Nov; 63(1):41. PubMed ID: 34732227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein.
    Anderson PM; Meyers DE; Hasz DE; Covalcuic K; Saltzman D; Khanna C; Uckun FM
    Cancer Res; 1995 Mar; 55(6):1321-7. PubMed ID: 7882330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.
    Meredith RF; Torgue JJ; Rozgaja TA; Banaga EP; Bunch PW; Alvarez RD; Straughn JM; Dobelbower MC; Lowy AM
    Am J Clin Oncol; 2018 Jul; 41(7):716-721. PubMed ID: 27906723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2.
    Mortensen ACL; Morin E; Brown CJ; Lane DP; Nestor M
    EJNMMI Res; 2020 Apr; 10(1):38. PubMed ID: 32300907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution study of
    Sakmár M; Kozempel J; Kučka J; Janská T; Štíbr M; Vlk M; Šefc L
    Nucl Med Biol; 2024; 130-131():108890. PubMed ID: 38402673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays.
    Larsen RH; Bruland OS; Hoff P; Alstad J; Lindmo T; Rofstad EK
    Radiat Res; 1994 Aug; 139(2):178-84. PubMed ID: 8052693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake, penetration, and binding of monoclonal antibodies with increasing affinity in human osteosarcoma multicell spheroids.
    Hjelstuen MH; Rasch-Halvorsen K; Bruland O; De L Davies C
    Anticancer Res; 1998; 18(5A):3153-61. PubMed ID: 9858878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.